Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
NCT ID: NCT06667414
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
600 participants
OBSERVATIONAL
2024-09-02
2028-09-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants Who Are Huntington Disease Gene Expansion Carriers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 25 to 60 years, inclusive, at the time of signing the ICF
* Confirmation of Huntington Disease (HD) gene expansion mutation carrier status
* Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) \>6 within 12 months prior to signing the ICF
* Ability to tolerate blood draws
Exclusion Criteria
25 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uab Medicine
Birmingham, Alabama, United States
Barrow Neurological Institute
Phoenix, Arizona, United States
University of California San Diego
La Jolla, California, United States
University of California Davis Medical System
Sacramento, California, United States
CenExel Rocky Mountain Clinical Research, LLC
Englewood, Colorado, United States
University of South Florida
Tampa, Florida, United States
Northwestern University
Chicago, Illinois, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
John Hopkins University School of Medicine
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
EvergreenHealth Investigational Drug Services
Kirkland, Washington, United States
Hospital Britanico de Buenos Aires
Ciudad Autonoma Buenos Aires, , Argentina
Calvary Health Care Bethlehem
Caulfield South, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Graylands Hospital
Mount Claremont, Western Australia, Australia
University of Alberta
Edmonton, Alberta, Canada
University of British Columbia Hospital
Vancouver, British Columbia, Canada
Centricity Research
Halifax, Nova Scotia, Canada
North York General Hospital
Toronto, Ontario, Canada
McGill University
Montreal, Quebec, Canada
Rigshospitalet, Hukommelsesklinikken
København Ø, , Denmark
Charité - Universitätsmed. Berlin, Klinik für Psychiatrie und Psychotherapie
Berlin, , Germany
St. Josef-Hospital, Neurologische Klinik der Ruhr-Uni
Bochum, , Germany
Universitätsklinikum Erlangen, Abteilung Molekulare Neurologie
Erlangen, , Germany
Universitätsklinikum Ulm
Ulm, , Germany
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Lombardy, Italy
Universita Degli Studi Di Firenze
Florence, Tuscany, Italy
Auckland DHB - Neurlogy Department
Auckland, , New Zealand
New Zealand Brain Research Institute
Christchurch, , New Zealand
Wellington Hospital
Wellington, , New Zealand
Szpital Sw. Wojciecha
Gda?sk, , Poland
Wojskowy Instytut Medycyny Lotniczej
Warsaw, , Poland
Unidade Local de Saude de Santa Maria, E.P.E. - Hospital de Santa Maria
Lisbon, , Portugal
CNS - Campus Neurológico
Torres Vedras, , Portugal
Hospital Universitario de Badajoz
Badajoz, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Hospital Universitario de Burgos. Servicio de Neurología
Burgos, , Spain
Hospital Ramon y Cajal
Madrid, , Spain
Birmingham and Solihull Mental Health Foundation NHS Trust
Birmingham, , United Kingdom
Addenbrookes Hospital
Cambridge, , United Kingdom
National Hospital For Neurology and Neurosurgery
London, , United Kingdom
John Radcliffe Hospital
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Reference Study ID Number: WE45491 https://forpatients.roche.com/
Role: CONTACT
Phone: 888-662-6728 (U.S. Only)
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WE45491
Identifier Type: -
Identifier Source: org_study_id